FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, and can be used for prediction restenosis stent in patients with ischemic heart disease 6 months after coronary stenting (CS). For this purpose, patients suffering ischemic heart disease on the first day of admission to hospital, before the coronary stenting and 6 months later, blood sampling is performed from the ulnar vein, method of enzyme immunoassay is used to determine the content α-defensins in blood plasma and determining the content ratio α-defenzines 6 months after operation/maintenance α-defensins before operation. That is followed by calculating the prognostic coefficient K by the formula K=exp(-5.9+(5.3)*x)/(1+exp(-5.9+(5.3)*x)), where K is the prognostic coefficient reflecting probability of development restenosis coronary stent, x is ratio of concentration change α-difensin 1-3 in blood plasma, calculated by dividing X2/X1: X1 is concentration α-difensin 1-3 in blood plasma before stenting in pg/ml, X2 is concentration α-difensin 1-3 in blood plasma 6 months after stenting in pg/ml. At value K≥0.357 considered risk of developing restenosis coronary stent 6 months after coronary stenting high if the value K<0.357, then the risk of developing restenosis coronary stent low.
EFFECT: method enables calculating risk of developing restenosis coronary stent and timely clinically justified decision on further management of the patient.
1 cl, 1 dwg, 2 ex
